Novartis is created through the merger of Ciba-Geigy and Sandoz.
Novartis ups its owndership of Roche stock to just under 33 percent.
Novartis Institutes for BioMedical Research opens as the firm's new global HQ.
The Novartis Institute for Tropical Disease opens in Singapore, focusing on dengue and TB.
Novartis nabs Hexel and Eon Labs, establishing Sandoz as the global no. 2 generics firm.
Novartis agrees to acquires British vaccine maker Chiron for $5.1 billion.
Novartis plans a biomedical R&D center in Shanghai.
The EU approves Sandoz's Omnitrope, the first-ever biosimilars product.
Novartis sells Gerber and its medical nutrition business to Nestle for $8 billion.
Novartis agrees to buy a majority share in eye-care company Alcon for $28.2 billion.
The Novartis Vaccines Institute for Global Health opens, focusing on neglected diseases.
On October 1, Novartis says it has begun delivery of its first batches of H1N1 flu vax to US.